The right treatment for every patient

AI-BASED PRECISION DIAGNOSTICS TO IMPROVE CANCER TREATMENT DECISIONS AND PATIENT OUTCOMES

Stratipath Breast

A CE-IVD solution for risk profiling of breast cancer,
the first-of-its-kind

The Research

From research to clinical use

About us

Stratipath is leveraging state-of-the-art deep learning technologies (AI) to provide risk profiling of cancer tumours.

News about Stratipath

Follow the news about Stratipath.

news

Work with us

Join our mission to improve patient outcomes.

Stratipath explained

Co-founder and professor of pathology, Johan Hartman, explains Stratipath in this 3 min video.

about stratipath

Stratipath is a spin-out of Karolinska Institutet in Stockholm, Sweden, leveraging state-of-the-art deep learning technologies (AI) to provide risk profiling of cancer tumours to healthcare and life science companies. Our cloud-based SaaS solutions are being used in clinical settings, having been developed based on years of ground-breaking research. We make precision diagnostics available to more patients at an affordable cost and in a fraction of the time compared to traditional methods.

Stratipath breast

Addresses the over 50% of breast cancers that are diagnosed as intermediate risk

Deep learning analysis of routine HE-stained histopathology images from resected breast tumours

Rapid analysis can shorten time to treatment

Contributes to reduced costs, time and workload

“Stratipath Breast offers a faster and cheaper alternative to molecular assays, allowing more patients to have access to precision diagnostics. By using Stratipath Breast, clinicians can diagnose with support from prognostic information, while reducing laboratory time and costs.”

Johan Hartman

Professor of pathology at Karolinska Institutet, Stockholm and co-founder of Stratipath.

Stratipath breast

Addresses the over 50% of breast cancers that are diagnosed as intermediate risk

Deep learning analysis of routine HE-stained histopathology images from resected breast tumours

Rapid analysis can shorten time to treatment

Contributes to reduced costs, time and workload

“Stratipath Breast offers a faster and cheaper alternative to molecular assays, allowing more patients to have access to precision diagnostics. By using Stratipath Breast, clinicians can diagnose with support from prognostic information, while reducing laboratory time and costs.”

Johan Hartman

Professor in pathology at Karolinska Institutet, Stockholm and co-founder of Stratipath.

Stratipath at a glance:

First-in-class solution

A paradigm shift in prognostic risk stratification of breast cancer, providing an alternative to expensive and time-consuming molecular assays.

Strong partnerships

For commercial rollout, distribution and optimal clinical workflow. SaaS solution integrated with leading digital pathology solutions.

Ongoing clinical implementation

In healthcare – oncology clinics and pathology labs.

AI platform & unique data

AI platform enabling rapid development, validation and deployment of AI-based precision diagnostics.

Clinical evidence

Published in high-impact journals and ongoing studies to support current and future solutions.

First-in-class solutions

A paradigm shift in prognostic risk stratification of breast cancer, providing an alternative to expensive and time-consuming molecular assays.

Strong partnerships

For commercial rollout, distribution and optimal clinical workflow. SaaS solution integrated with leading digital pathology solutions.

Ongoing clinical implementation

In healthcare – oncology clinics and pathology labs.

AI platform & unique data

AI platform enabling rapid development, validation and deployment of AI-based precision diagnostics.

Clinical evidence

Published in high-impact journals and ongoing studies to support current and future solutions.